Pharmaceutical manufacturer Actavis has completed the acquisition of American firm Allergran in a cash and equity deal valued at approximately $70.5bn.
Actavis said the acquisition created one of the world's top 10 pharmaceutical companies by sales revenue, with combined annual pro forma revenues of more than $23bn anticipated in 2015. It added that the deal would bring a strengthened and expanded pharmaceutical R&D pipeline and enhanced commercial opportunities across global markets.
‘Our combined company will be built around a customer-focused commitment to partnering with physicians, pharmacists and patients to deliver innovative treatments and enhance access to important therapies around the world. We have industry-leading global commercial strength, with sustainable blockbuster brand franchises in key therapeutic categories and broad commercial reach extending across approximately 100 countries, said Brent Saunders,’ CEO and president of Actavis.
Register now to continue reading
Thank you for visiting Optician Online. Register now to access up to 10 news and opinion articles a month.
Register
Already have an account? Sign in here